This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: What Was Bad Is Good Again

With the stock's remarkable run, Cramer said the market has spoken loudly that it feels Pirfenidone will be a blockbuster. He said investors need to do their homework and have conviction to own a biotech like InterMune in a market that has become extremely fickle.

The Wrong Sporting Trade

Don't take your cues from the wrong companies, Cramer reminded viewers. Case in point: Dick's Sporting Goods (DKS), which saw its shares decline by 18% after the company posted miserable results, with same-store sales rising just 1.5% when analysts were expecting 3% to 4%.

Cramer said the miserable results from Dick's took down all the sporting goods stocks, including Cabela's (CAB), down 5%, and Sportsman's Warehouse (SPWH), down a whopping 16%.

But the problem is not with sporting goods, Cramer told viewers, it's with Dick's and some hig- profile mistakes its management has been making. First, the company doubled down on golf, opening a whole chain dedicated to the sport. Second, the company opted to stop selling some popular high-power sporting rifles last year. Cramer said that decision may make for good public policy but it has been very bad for business.

Yet, both Cabela's and Sportsman's Warehouse don't suffer from either of these issues, Cramer said, and thus don't deserve the slamming they received. Cabela's reaffirmed its guidance when it reported a month ago, and Sportsman's remains an attractive regional to national growth story.

Cramer said he'd pickup either of these two names as they've both gotten very inexpensive.

Executive Decision: Dr. Phil Frost

In his second "Executive Decision" segment, Cramer sat down with Dr. Phil Frost, chairman and CEO of Opko Health (OPK), the diagnostics and drug company that's seen a 70% gain in its shares since Cramer first got behind the stock in October 2011.

Dr. Frost once again touted his company's 4Kscore product, which is a confirmation test for prostate cancer that could eliminate 40% to 50% of all biopsies performed in the U.S., saving the health care system millions of dollars and patients the inconvenience of undergoing the procedure

Dr. Frost also talked about Opko's Claros-1 test card, which eliminates the need to ship a patient's blood off to a lab for testing, and instead provides results in just 10 minutes with just a single drop of blood.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,190.83 -88.91 -0.51%
S&P 500 1,993.72 -16.68 -0.83%
NASDAQ 4,517.2660 -62.5230 -1.37%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs